Stay updated on Amgen Press Releases
Sign up to get notified when there's something new on the Amgen Press Releases page.
Latest updates to the Amgen Press Releases page
- Check7 days agoChange DetectedAMGEN has announced its 2025 first quarter dividend.SummaryDifference16%
- Check14 days agoChange DetectedAmgen has made significant announcements, including the addition of BLINCYTO® for pediatric B-ALL treatment, a $1 billion manufacturing expansion in North Carolina, and positive results for various drugs in clinical trials, highlighting advancements in oncology and rare diseases.SummaryDifference100%
- Check21 days agoChange DetectedAmgen has made significant announcements regarding new data presentations and executive appointments, while notable deletions include various financial results and conference presentations from late 2024.SummaryDifference100%
- Check28 days agoChange DetectedAmgen has announced several significant updates, including a senior executive research appointment, new data presentations at major conferences, and the approval of Tepezza® in Japan for active thyroid eye disease.SummaryDifference100%
- Check65 days agoChange DetectedAmgen has recently presented positive Phase 3 data for Uplizna® in generalized myasthenia gravis and received approval for Tepezza® in Japan for active thyroid eye disease, highlighting significant advancements in their clinical research and product offerings.SummaryDifference100%
- Check94 days agoChange DetectedAmgen has made significant updates, including the FDA approval of IMDELLTRA™ for extensive-stage small cell lung cancer and the launch of OTEZLA® for pediatric plaque psoriasis, while several upcoming presentations and financial results have been removed from the site.SummaryDifference100%
Stay in the know with updates to Amgen Press Releases
Enter your email address, and we'll notify you when there's something new on the Amgen Press Releases page.